Martin Shkreli Exits Long Valeant Pharma (VRX)/short Allergan (AGN) Trade for Loss of 3%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- Nasdaq ends sharply higher; chip surge offsets Iran worries
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices settle 2% lower as economic worries outweigh supply risks
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- GameStop stockholders approve share count increase to 2.5 billion
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
- Key things to know ahead of SK Hynix’s blockbuster US listing
Leerink PartnersRaises Price Target on Allergan (AGN) Following a MEDACorp Survey
October 28, 2015 7:05 AM EDTLeerink Partners reiterated an Outperform rating on Allergen (NYSE: AGN), and raised the price target to $342.00 (from $311.00), following a 60 person MEDACorp survey of US plastic surgeons and dermatologists. Specialists in the survey were bullish on Kybella and expect the drug to increase their submental fat patient... More
BTIG Thinks Valeant (VRX) Should Just Severe Ties with Philidor; PT Cut to $175
October 26, 2015 2:53 PM EDTBTIG is cutting its price target on Valeant Pharma (NYSE: VRX) from $210 down to $175, but maintaining a Buy rating following this morning's conference call.
Analyst Timothy Chiang commented, More details were provided this morning on Valeants call highlighting its relationship with Philidor,... More
